Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Addition to First-line Chemotherapy for Classical Hodgkin Lymphoma
NCT07720011Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2019
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in classical Hodgkin lymphoma (cHL), sponsored by Peking University People's Hospital. Started Feb 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07720011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720011.